# ASTX727 & Retifanlimab-dlwr for Advanced Merkel Cell After Progression on Anti-PD-(L)1

> **NCT07472322** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **University of Wisconsin, Madison** · enrollment: 31 (estimated)

## Conditions studied

- Merkel Cell Carcinoma
- Merkel Cell Carcinoma, Stage III
- Merkel Cell Carcinoma, Stage IV

## Interventions

- **DRUG:** ASTX727 + retifanlimab

## Key facts

- **NCT ID:** NCT07472322
- **Lead sponsor:** University of Wisconsin, Madison
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05
- **Primary completion:** 2031-05
- **Final completion:** 2031-05
- **Target enrollment:** 31 (ESTIMATED)
- **Last updated:** 2026-04-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07472322

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07472322, "ASTX727 & Retifanlimab-dlwr for Advanced Merkel Cell After Progression on Anti-PD-(L)1". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07472322. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*